Rockwell Medical Inc (RMTI) reported quarterly earnings results on Tuesday, May-10-2016. The company said it had a profit of $-0.10 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.02. Analysts had a consensus of $-0.12. The company posted revenue of $13.63 million in the period, compared to analysts expectations of $15.65 million. The company’s revenue was down -1.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.07 EPS.
Many Wall Street Analysts have commented on Rockwell Medical Inc. Rockwell Medical Inc was Downgraded by Stifel to ” Hold” on Mar 1, 2016.
Rockwell Medical Inc closed down -0.69 points or -8.87% at $7.09 with 3,48,619 shares getting traded on Friday. Post opening the session at $7.62, the shares hit an intraday low of $7.03 and an intraday high of $7.64 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
In a different news, on Dec 8, 2015, Ronald D Boyd (director) sold 12,500 shares at $10.59 per share price. According to the SEC, on Nov 13, 2015, Kenneth L Holt (director) sold 7,934 shares at $8.83 per share price. On Aug 14, 2015, Robert L Chioini (CEO) purchased 4,910 shares at $11.96 per share price, according to the Form-4 filing with the securities and exchange commission.
Rockwell Medical Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency secondary hyperparathyroidism and hemodialysis. The Company’s lead branded drug Triferic is approved by the United States Food and Drug Administration (FDA). Triferic is an iron compound that is delivered to hemodialysis patients via dialysate replacing the iron loss that occurs during their dialysis treatment. Triferic enters the blood and immediately binds to transferrin and is transported to the erythroid precursor cells to be incorporated into hemoglobin. Rockwell’s generic drug Calcitriol is indicated for treating secondary hyperparathyroidism in dialysis patients. The Company manufactures sells delivers and distributes hemodialysis concentrates along with a range of ancillary products.